GRI Bio receives Nasdaq deficiency notice for bid price below $1; 180-day cure period until March 10, 2025

GRI Bio, Inc.

Received Nasdaq letter on Sept 10, 2024 for failing minimum bid price of $1.00 over 30 consecutive business days.
Has until March 10, 2025 (180 days) to regain compliance by closing at $1.00+ for 10 consecutive business days.
If stock closes at $0.10 or less for 10 consecutive trading days during cure period, Nasdaq may issue delisting determination.
Company may be eligible for an additional 180-day extension if it meets other Nasdaq listing conditions.
Management is monitoring the bid price and evaluating options to regain compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.